targeting signal for the regulated pathway.
J
Clin lnvest
1993;92:1042-54.
Il.
Galindo E, Mendez M, Calvo S, Gonzalez-Garcia C,
CenaV,HubertP, et al. Chromostatin receptors controlcalcium
channel activity in adrenal chromaffine cells. J Bio! Chem
1992;264:12009-15.
12. HåkanssonR, DingX-Q, Norlen P, Chen D.Circulating
pancreastatin is amarker for theenterochromaffine-likecellsof
the rat stomach. Gastroenterology 1995;108:1445-52.
13. Marchisic PC, Corti A, Siccardi AG. Chromogranin A:
general biology [Abstract]. Tumori neuroendocrini. Sympo–
sium Turin 22-23 mars 1996, p. 27.
14. OTonnor DT, Deftos U . Secretion of chromogranin A
by peptide-producing endocrine neoplasms. N Engl J Med
1986;314:1145-51.
15. Cubeddu LX, O'Connor DT, Hoffman I, Parmer J.
Plasma chromogranin A marks emesis and seratonin release
associated with dacarbazine and nitrogen mustard but not with
cyclophosphamide-based chemotherapies. Br J Cancer
1995;72: l033-8.
16. Cubeddu LX, OTonnor DT, Parmer
J.
Plasma
chromograninA: amarker of seratonin release associated with
cisplatin chemotherapy. J Clin Oncoll995;13:681-7.
17. Hsiao RJ, Neumann HPH, Parmer RJ, Barhosa JA,
O'ConnorDT.ChromograninA in familial pheochromocytoma:
diagnostic screening value, prediction of turnormass, and post–
resectionkinetics indicating two-compartmentdistribution. Am
J Med 1990;88:607-13.
18. Hsiao RJ,MezgerMS, O'Connor DT. Chromogranin in
52
uremia: progressive retention of immunoreactive fragments.
Kidney lnt 1990;37:955-64.
19. Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B,
Nilsson-Ehle P, Lindström V, Grubb A. Serum cystatin C,
determinedbyarapid,automatedparticle-enhanced turbidimetric
method, is a bettermarkerthan serum creatinine for glomerular
filtration rate. C!in Chem 1994;40: 1921-6.
20. Hsiao RJ, Parmer RJ, Takiyyuddin MA, O'Connor DT.
ChromograninA storage and secretion: sensitivity and specifi–
city for the diagnosis of pheochromocytoma. Medicine
1991;70:33-45.
21. O'Connor DT, Pandian MR, Carlton E, Cervenka JH,
HsiaoRJ.Rapid radioimmunoassayofcirculatingchromogranin
A: invitro stabiiity, explorationofthe neuroendocrinecharacter
ofneoplasia, and assessment oftheeffectsoforgan failure. Clin
Chem 1989;35:1631-7.
22. Sobol RE, Memoli V, Deftos U . Hormone-negative,
chromogranin A-positive endocrine tumors. N Engl J Med
1989;320:444-7.
23. Hsiao RJ, Seeger RC, Yu AL, O'Connor DT.
Chromogranin A in children with neuroblastoma. Serum con–
centration parallells disease stage and prediets survival. J Clin
Invest 1990;85: 1555-9.
24.StabileBE,Howard
TJ,
PassaroE,OTonnorDT.Source
of plasma chromogranin A elevation in gastrinorna patients.
Arch Surg 1990;125:451-3.
25.SyversenV,MignonM,BonfilsS,KristensenA,Waldum
HL.Chromogranin A and pancreastatin-like immunoreactivity
in serum ofgastrinorna patients. Acta Oncol 1993;32:161-5.
Klinisk Kemi
i
Norden
2,
1996
